| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Contract revenue | $1.6M+58.9% | $1.0M | $0 | — | $2.7M |
| Research and development | $20.2M-24.3% | $26.7M-32.7% | $39.6M+8.2% | $36.6M+38.2% | $26.5M |
| General and administrative | $19.7M-17.6% | $23.9M-9.6% | $26.5M-1.4% | $26.8M-3.6% | $27.8M |
| Impairment loss | $0-100.0% | $3.7M | $0 | — | — |
| Total operating expenses | $39.9M-26.5% | $54.3M-17.8% | $66.1M+4.2% | $63.5M+16.8% | $54.3M |
| Loss from operations | -$38.3M+28.1% | -$53.3M+19.3% | -$66.1M-4.2% | -$63.5M-23.0% | -$51.6M |
| Interest income and other, net | $827K-53.1% | $1.8M-46.6% | $3.3M+164.5% | $1.2M+1302.2% | $89K |
| Interest expense and other, net | -$2.9M+42.6% | -$5.0M+1.0% | -$5.1M-374.8% | -$1.1M-129.8% | -$466K |
| Loss on extinguishment of debt | -$576K | $0 | — | — | -$700K |
| Net loss | -$41.0M+27.6% | -$56.6M+16.6% | -$67.9M-7.2% | -$63.3M-19.3% | -$53.1M |
| Net loss attributable to non-controlling interest | -$11.3M+57.6% | -$26.6M+21.7% | -$33.9M-3.5% | -$32.8M+26.8% | -$44.8M |
| Net loss attributable to Rani Therapeutics Holdings, Inc. | -$29.7M+1.1% | -$30.0M+11.6% | -$34.0M-11.1% | -$30.6M-267.2% | -$8.3M |
| Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.-basic | -$450+57.1% | -$1K+21.1% | -$1K-3.9% | -$1K-197.7% | -$430 |
| Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.-diluted | -$450+57.1% | -$1K+21.1% | -$1K-3.9% | -$1K-197.7% | -$430 |
| Weighted average Class A common share outstanding-basic | $66.1M+132.3% | $28.5M+11.6% | $25.5M+7.1% | $23.8M+21.9% | $19.5M |
| Weighted average Class A common share outstanding-diluted | $66.1M+132.3% | $28.5M+11.6% | $25.5M+7.1% | $23.8M+21.9% | $19.5M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.